ClinicalTrials.gg
CompletedNCT05971836Updated Jul 13, 2026

The Molecular Basis of Inherited Reproductive Disorders

An observational study in Hypogonadotropic Hypogonadism, Reproductive Disorder and Kallmann Syndrome, sponsored by Stephanie B. Seminara, MD. Completed at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Primary conditionKallmann SyndromeRegistry: HypogonadismReclassifiedWhy we changed it
Registry
Hypogonadism — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kallmann Syndrome
Why
  1. The study's listed conditions name Kallmann Syndrome, a narrower term within Hypogonadism.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Stephanie B. Seminara, MD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
854
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Kallmann Syndrome with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Kallmann Syndrome · United States.

Started
2021
the only one that year
Observational
6 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
Stephanie B. Seminara, MD

Among the 16 studies in Kallmann Syndrome with a site in United States, this one is the only one that started in 2021, is one of 6 observational ones, and was the 16th registered.

Kallmann Syndrome

23 studies on the registry are indexed under Kallmann Syndrome; 5 are open to participants now.

Browse Kallmann Syndrome studies →

Open to participants now

1 of the 16 studies in Kallmann Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Kallmann Syndrome studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Kallmann Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn more about the genes that control puberty and reproduction in humans.

Read the detailed description

All study subjects will undergo the same activities. Subjects will provide up to five tubes of blood for genetic analysis, complete a smell test, and answer questions about their health and family history.

03

Conditions studied

  • Hypogonadotropic Hypogonadism
  • Reproductive Disorder
  • Kallmann Syndrome
  • Delayed Puberty

Browse trials for

Keywords

  • Hypogonadotropic hypogonadism
  • Reproductive disorders
  • Kallmann syndrome
  • Kisspeptin
  • Delayed Puberty
04

In context

Kallmann Syndrome Reclassified

23 studies on the registry are indexed under Kallmann Syndrome; 5 are open to participants now.

Browse Kallmann Syndrome studies →

Lead sponsor

Stephanie B. Seminara, MD is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Compared within Kallmann Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypogonadism. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Healthy controls and individuals with reproductive disorders and their affected and unaffected family members

Eligibility criteria

Participants must be healthy controls or belong to one of the following categories:

  • Failure to go through a normal, age-appropriate, spontaneous puberty and low sex levels in the setting of low/normal gonadotropins or,
  • Abnormally early development of puberty or,
  • Normal puberty with subsequent development of low gonadotropin levels or,
  • Evidence of a reproductive disorder with high gonadotropin levels or,
  • Pre-pubertal individuals with features suggestive of hypogonadotropic hypogonadism or,
  • Affected and unaffected family members of individuals that fit criteria above
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
854 participants (actual)
Patient registry
No

Groups and cohorts

  • Subjects with Reproductive Disorders or Healthy controls

    Healthy controls or individuals with reproductive disorders and their affected and unaffected family members

07

What researchers measure

Primary outcomes

  1. Genetic variation

    Identification of one or more genetic variations related to reproductive disorders

    Time frame: Day 1

08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2026, 62 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Aug 2, 2023
StartActual
Jan 21, 2021
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05971836
Lead sponsor
Stephanie B. Seminara, MD
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
Aug 2, 2023
Start date
Jan 21, 2021
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Jul 13, 2026

Study contacts

Stephanie Seminara, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion